A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

the active ingredient in Eli Lilly’s Zepbound. A recent study found that participants who used the GLP-1 medications without exercising experienced a significant decrease in bone density at ...